Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis Inc (PSNL) drives innovation in genome-guided medicine through advanced sequencing solutions and cancer immunotherapy research. This news hub provides investors and researchers with essential updates on the company’s scientific advancements and strategic developments.
Access authoritative reporting on PSNL’s financial results, clinical trial milestones, and technology partnerships. Our curated collection includes press releases on pharmacogenomics breakthroughs, regulatory filings, and collaborative research initiatives shaping personalized medicine.
Key coverage areas include precision oncology developments, genomic data platform enhancements, and biopharma collaborations. Stay informed about innovations in neoantigen discovery and therapeutic vaccine development through verified primary sources.
Bookmark this page for real-time updates on Personalis’ contributions to next-generation diagnostics and therapeutic solutions. Monitor critical updates through our organized repository of corporate communications and third-party analysis.
Personalis, Inc. (Nasdaq: PSNL) has initiated a public offering of $150 million in common stock, with a potential additional $22.5 million available through underwriter options. This move is contingent on market conditions, and the completion date is uncertain. The offering is supported by major financial institutions including Morgan Stanley and BofA Securities. A registration statement for the shares was previously filed with the SEC. Investors are cautioned about the risks associated with the offering, including market unpredictability and regulatory compliance.
Personalis, Inc. (Nasdaq: PSNL) announced preliminary revenue for Q4 and full year 2020, estimating $20.2 million for Q4, an 11% increase from $18.2 million in Q4 2019. Full year revenue reached $78.6 million, up 21% from $65.2 million in 2019. Key highlights include a 73% increase in biopharma revenue to $7.6 million, although revenue from the VA Million Veterans Program fell 9% to $12.6 million. Cash reserves were estimated at $203 million as of December 31, 2020.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 2:45 p.m. Eastern Time. The company specializes in population sequencing and oncology, offering advanced molecular data to improve cancer treatment. Its ImmunoID NeXT Platform analyzes approximately 20,000 human genes and immune responses from a single tissue sample, supporting biopharmaceutical development. Personalis is recognized for its extensive sequencing operations and is the exclusive sequencing provider for the VA MVP.
Personalis, Inc. (Nasdaq: PSNL) has launched its innovative Neoantigen Presentation Score (NEOPS), which enhances cancer therapy predictions by integrating tumor neoantigen analysis with immune evasion mechanisms. NEOPS leverages the SHERPA™ tool and the Personalis NeXT Platform™ to improve patient stratification for immunotherapy responses. Data from an AACR meeting showcased NEOPS's superior predictive capabilities over traditional metrics like tumor mutational burden in late-stage melanoma patients. This development positions NEOPS as a vital tool for future clinical trials.
Personalis, Inc. (Nasdaq: PSNL) has launched its proprietary SHERPA tool, a machine learning algorithm designed for identifying cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA is set to enhance the development of novel neoantigen-based diagnostic biomarkers, such as the Neoantigen Presentation Score (NEOPS™). Data from the SITC Annual Meeting indicates SHERPA exceeds traditional neoantigen prediction methods. The tool is also being utilized by Sarepta Therapeutics for precision genetic therapeutics, highlighting its versatility beyond oncology.
Personalis, Inc. (Nasdaq: PSNL) announced its upcoming presentation of clinical data for the NeXT DxTM test at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster, titled “An exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients,” will take place on Nov 17th between 1-2pm EST. The NeXT Dx test provides a diagnostic report on genomic alterations in 247 cancer-related genes and offers therapy recommendations, clinical trial matching, and biomarker results.
Personalis, Inc. (Nasdaq: PSNL) will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online from November 11-14. The company will present its ImmunoID NeXT™ platform, which enables comprehensive analysis of tumors and their immune microenvironment from a single sample. Key poster presentations include topics like tumor circulating cell-free DNA profiling and precision neoantigen discovery. Additionally, an industry symposium on maximizing immunotherapy biomarker discovery will take place on November 12.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in upcoming investor conferences. The company will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 4:15 p.m. ET. Additionally, it will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020. Personalis focuses on providing comprehensive molecular data through its ImmunoID NeXT Platform, aimed at enhancing cancer therapy development. The firm is also involved in the VA Million Veterans Program to sequence veteran genomes.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will release its Q3 2020 financial results on November 5, 2020, post-market. A conference call and webcast will be held at 2:00 PM PT / 5:00 PM ET to discuss these results and recent developments. The company specializes in advanced genomic solutions for cancer, utilizing its ImmunoID NeXT Platform to analyze 20,000 human genes and immune responses from patient samples. Personalis is also partnering with the VA Million Veterans Program to sequence over two million veteran genomes.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
